A study conducted at The Department of Urology, Yokosuka Kyosai Hospital, Japan, evaluated the efficacy and safety of using a low-dose chemotherapy combination of docetaxel, estramustine and dexamethasone in men with castrate resistant prostate cancer (CRPC). The study enrolled sixty-nine with CRPC. Docetaxel dosage was downed to 25 mg/m2 on days 1 and 8 every [...]
In June of 2009 a team at UCSF Department of Urology announced a new prostate cancer risk assessment test that they claim can provide men and their doctors a better way of gauging long-term risks and pinpointing high risk cases of prostate cancer. The test, as indicated by the researchers, proved accurate in predicting bone [...]
President Barack Obama has nominated Harold E. Varmus, M.D., the Nobel Prize-winning scientist for studies showing how certain normal genes could cause cancer when they went awry; to serve as the 14th director of the National Cancer Institute (NCI). Dr. Varmus served as director of the National Institutes of Health in the 1990s, a period [...]
Don Greggs, a long time prostate cancer survivor, recently asked his niece if people with cancer are able to donate organs at the time of their death. His niece who has worked in the organ recovery field gave him an answer that surprised me. She said that having cancer does not eliminate the possibility of [...]
We know that approximately one-third of all men who elect to have a radical prostatectomy for localized prostate cancer will ultimately experience a biochemical (PSA) recurrence. Researchers at the Department of Urology, Loyola University Medical Center, Maywood, IL, report on their long-term outcomes of salvage radiotherapy (SRT). […]